Clinical Trial Update: Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial update evaluating the role of Ga-68 PSMA-11 PET-CT in guiding therapeutic decisions after initial staging for high-risk prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: UNKNOWN